Journal of Neuro-Oncology

, Volume 64, Issue 1, pp 13–20 | Cite as

Autologous Glioma Cell Vaccine Admixed with Interleukin-4 Gene Transfected Fibroblasts in the Treatment of Recurrent Glioblastoma: Preliminary Observations in a Patient with a Favorable Response to Therapy

  • Hideho Okada
  • Frank S. Lieberman
  • Howard D. Edington
  • Timothy F. Witham
  • Mark J. Wargo
  • Quan Cai
  • Elaine H. Elder
  • Theresa L. Whiteside
  • S. Clifford ScholdJr.
  • Ian F. Pollack


We designed a phase I clinical trial of vaccinations with autologous glioma cells expressing transgene-derived interleukin-4 (IL-4), and treated one patient with a right temporal lobe recurrent glioblastoma. This 62-year-old man underwent craniotomy and partial tumor removal, at which time autologous tumor cells were obtained for vaccine preparation. After confirming the patient's cellular immune function by skin test, two cycles of vaccination with irradiated autologous glioma cells admixed with gene transfected fibroblasts were given intradermally. The patient demonstrated no evidence of allergic encephalitis throughout this course. Immunohistochemistry with biopsy samples taken from the vaccine sites demonstrated that the infiltration level of CD4, CD8 and CD1a positive cells increased proportionally to the amount of IL-4 produced at the each site, suggesting that there was local immune response induced at the vaccine site. While it is premature to assess effectiveness of the vaccine, this initial patient's course suggested a transient response to the vaccine, and he survived 10 months after treatment.

cancer vaccine gliomas interleukin-4 immunotherapy retroviral vectors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dranoff G: Cancer gene therapy: connecting basic research with clinical inquiry. [Review] [85 refs]. J Clin Oncol 16: 2548–2556, 1998Google Scholar
  2. 2.
    Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the immunologically privileged central nervous system. Proc Natl Acad Sci USA 93: 10399–10404, 1996Google Scholar
  3. 3.
    Dranoff G: The use of gene transfer in cancer immunotheraphy. [Review] [48 refs]. Forum 8: 357–364, 1998Google Scholar
  4. 4.
    Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generated potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95: 13141–13146, 1998Google Scholar
  5. 5.
    Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama HB, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cerlls engineered to secrete interleukin-4. Science 254: 713–716, 1991Google Scholar
  6. 6.
    Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musinani P, Modesti A, Cavallo F, Di Pierro F, Novelli F, Forni G: An efficient Th2-type memory follows CD8+ lymphocytedriven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 153: 5659–5673, 1994Google Scholar
  7. 7.
    Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T: TH1-associated and cytotoxic T lymphocyte-mediated tumor immunity is imparied in IL-4-deficient mice. J Exp Med 189: 803–810, 1999Google Scholar
  8. 8.
    Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT: Local IL-4 delivery enhances immune reactivity to murine tumors: gene theraphy in combination with IL-2. Cancer Gene Ther 1: 35–42, 1994Google Scholar
  9. 9.
    Stoppacciaro A, Paglia P, Lambardi L, Parmiani G, Baroni C, Colombo MP: Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 27: 2375–2382, 1997Google Scholar
  10. 10.
    Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin, Posner M, Rosenfelder D, Watson C: Gene theraphy of cancer: a pilot study of IL-4-genemodified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5: 41–55, 1994Google Scholar
  11. 11.
    Suminami Y, Elder Em, Lotze MT, Whiteside TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother 17: 238–248, 1995Google Scholar
  12. 12.
    Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, De Tribolet N, Tschopp TJ, Diertrich PY: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173–1178, 1997Google Scholar
  13. 13.
    Weller M, Fontana A, The failure of current immunotheraphy for malignant glioma. Tumor-derived TGF-beta. T-cells apoptosis, and the immune privilege of the brain. Brain Res 21: 128–151, 1995Google Scholar
  14. 14.
    Wiendel H, Mitsdoerffer M, Hofmeister V, Wischhuyse J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M: A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168: 4772–4780, 2002Google Scholar
  15. 15.
    Wischhusen J, Jung G, Radovanovoc I, Beier C, Steibach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M: Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62: 2592–2599, 2002Google Scholar
  16. 16.
    Lampson LA: Beyond inflammation: site-directed immunotheraphy. [Review] [32 refs]. Immunol Today 19: 17–22, 1998Google Scholar
  17. 17.
    Lampson LA: Immunobiology of brain tumors: anigens, effectors, and delivery to sites of microscopic tumor in the brain. In: Black PM, Loeffler JS (eds) Cancer of the Nervous System. Blackwell, Oxford, 1997, pp 874–906Google Scholar
  18. 18.
    Okada H, Villa LA, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH: Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 8: 1157–1166, 2001Google Scholar
  19. 19.
    Elder EM, Lotze MT, Whiteside TL: Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther 7: 479–487, 1996Google Scholar
  20. 20.
    Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine. Gene Ther 6: 219–226, 1999Google Scholar
  21. 21.
    Giezeman-Smits KM, Okada H, Brissette-Storkus SC, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH: Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60: 2449–2457, 2000Google Scholar
  22. 22.
    Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman FS, Schiff D, Attanucci J, Edington H, Chambers WH, Robbins PD, Baar J, Kinzler D, Whiteside TL, Elder EM: Gene therapy of malignant gliomas: a phase I study of IL4HSV-TK gene-modified autologous tumor to elicit an immune response (clinical protocol). Hum Gene Ther 11: 637–653, 2000Google Scholar
  23. 23.
    Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT: Characterization and transduction of a retroviral vector encoding human interleukin-4 and the herpes simplex-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther 7: 486–494, 2000Google Scholar
  24. 24.
    Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T: The use of computer – assited video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha sopots in response to peptide antigens. J Immunol Methods 203: 141–152, 1997Google Scholar
  25. 25.
    Kalman B, Lublin FD: Immunopathogenic mechanisms in experimental allergic encephalomyelitis. [Review]. Curr Opin Neurol Neurosurg 6: 182–188, 1993Google Scholar
  26. 26.
    Schmidt S, Linington C Zipp F, Sotgiu S, de Wall Malefyt R, Wekerle H, Hohlfeld R: Multiple sclerosis: comparison of the human T-cell response to S100 beta ansd myelin basic protein reveal oparallels to rat experimental autoimmune panencepohalitis. Brain 120: 1437–1445, 1997Google Scholar
  27. 27.
    Bigner DD Pitts OM, Wikstrand CJ: Induction of lethal experimental allergic encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 55: 32–42, 1981Google Scholar
  28. 28.
    Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ: Mature dentritic cells pulsed with free-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96, 1857–1864, 2000Google Scholar
  29. 29.
    Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CLJ, Sidney J, Sette A, Storkus WJ: Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanomareactive CD4(+) T cells. Proc Natl Acad Sci USA 97: 400–405, 2000Google Scholar
  30. 30.
    Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H: Identification of a novel HLA-A*0201 restricetd cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin Cancer Res 8: 2851– 2855, 2002Google Scholar
  31. 31.
    Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5: 985–990, 1999Google Scholar
  32. 32.
    Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY: Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48: 103–111, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Hideho Okada
    • 1
    • 2
    • 3
  • Frank S. Lieberman
    • 4
  • Howard D. Edington
    • 2
  • Timothy F. Witham
    • 1
  • Mark J. Wargo
    • 3
  • Quan Cai
    • 2
  • Elaine H. Elder
    • 5
  • Theresa L. Whiteside
    • 5
  • S. Clifford ScholdJr.
    • 4
  • Ian F. Pollack
    • 1
  1. 1.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicineUSA
  2. 2.Department of SurgeryUniversity of Pittsburgh School of MedicineUSA
  3. 3.Neuro-Oncology ProgramUniversity of Pittsburgh Cancer InstituteUSA
  4. 4.Department of NeurologyUniversity of Pittsburgh School of MedicineUSA
  5. 5.Department of PathologyUniversity of Pittsburgh School of MedicineUSA

Personalised recommendations